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The toxic oil syndrome in Spain affected >20,000 people. In the 
initial stages, it was characterized by a respiratory distress 
syndrome with myalgias and eosinophilia. Pulmonary hyperten-
sion developed in 20% of the patients and in many, it has 
spontaneously regressed. Nevertheless, in a smllll subgroup, it has 
progressed to a malignant course of cor pulmonale, leading 
rapidly to death. 
Clinical and pathologic features of 40 patients with severe 
pulmonary hypertension due to the toxic oil syndrome are pre-
sented (32 female and 8 male patients; mean age 26 ± 13 years). 
In May 1981, an epidemic appeared in Spain as a result of the 
ingestion of a toxic oil that affected >20,000 people (1). The 
World Health Organization (WHO) designated this disease 
as toxic oil syndrome. In its initial stages, the syndrome was 
characterized by an acute respiratory distress syndrome 
with myalgias and eosinophilia. Pulmonary hypertension 
developed in 20% of the patients. Muscular involvement and 
neurologic dysfunction followed the initial stage, leading to 
chronic respiratory failure (2). In many victims, the pulmo-
nary hypertension spontaneously regressed. FoJJr years after 
the onset of the syndrome, the prevalence of pulmonary 
hypertension was about 1.5%. Nevertheless, a small sub-
group of patients with pulmonary hypertension has exhibited 
a malignant course, leading rapidly to death. In these pa-
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The study began in June 1981, which was near the onset of the 
toxic oil epidemic, and ended in December 1987, >6 years later. 
The pulmonary hypertension is clinically and pathologically indis-
tinguishable from primary pulmonary hypertension. Direct endo-
thelial injury by the toxic agent is proposed as the initial trigger of 
this type of pulmonary hypertension, but an interaction between 
the toxic agent and specific individual susceptibility is probably 
required in its pathogenesis. 
(JAm Coli Cardio/1991;18:1539-45) 
tients, both pathologic and clinical studies disclosed findings 
similar to those of primary pulmonary hypertension. The 
actual incidence of this severe form is 1.6 per 1,000 (3). This 
report presents the clinical and pathologic features of 40 
patients with severe pulmonary hypertension due to toxic oil 
syndrome. 
Methods 
Study patients. Forty patients affected with the toxic oil 
syndrome with symptoms and signs of severe pulmonary 
hypertension participated in this study. The mean age 
(± SD) of the patients was 26 ± 13 years (range 8 to 58). 
Thirty-two were female and eight were male (female/male 
ratio 4: 1). The follow-up study of these patients started in 
June 1981 and ended in December 1987, with a mean 
follow-up period of 36 ± 30 months (range 1 to 80). Thirty-
three patients died during the follow-up period (24 in the 
initial 4 years and 9 in the last 2 years). 
Clinical studies. Clinical history, physical examination, 
electrocardiogram (ECG), chest X-ray film, pulmonary func-
tion and Doppler echocardiographic data were obtained in all 
patients. 
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Hemodynamic study. Because of the severity of illness in 
some of the subjects, hemodynamic study was performed in 
only 24 patients. Right and left heart catheterization was 
performed with standard techniques, obtaining the following 
measurements: l) right atrial, right ventricular and main 
pulmonary artery pressures; 2) aortic, left ventricular and 
pulmonary wedge pressures; 3) cardiac output by thermodi-
lution technique; and 4) pulmonary and systemic resis-
tances. 
Pathologic studies. Autopsy and pathologic studies were 
performed in 28 of the 33 patients. Lung specimens were 
fixed in formaldehyde and slices from different zones of each 
lobule were stained with use of conventional techniques 
(hematoxylin-eosin, van Gieson, orcein). Histologic severity 
of pulmonary vessel involvement was graded according to 
the Heath and Edwards classification (4). In 10 patients, 
vascular lesions were also assessed by a linear morphomet-
ric method with a micrometric eyepiece (5). A thickness of 
the tunica media of <7% was considered normal (6). 
Statistical analysis. This was performed using the Stu-
dent's t test and chi-square analysis with Yates' correction. 
A p value <0.05 (two-tailed) was considered significant. 
Results 
Clinical Features 
Clinical manifestations. Dyspnea was present in all pa-
tients, angina pectoris in 18 (45%), syncope in 14 (32.5%) and 
fatigue in 29 (72.7%). Angina was associated with the highest 
pulmonary artery pressures and lowest cardiac output (p < 
0.01). Other clinical manifestations of the toxic oil syndrome 
unrelated to pulmonary hypertension were neuromuscular 
involvement in 31 (77. 7%), biochemical evidence of liver 
damage in 17 (42.5%), scleroderma-like lesions in 25 
(62.5%), Raynaud's phenomenon in 3 (7.5%) and dysphagia 
in 5 (12.5%). 
Physical examination. Elevated venous pressure was 
present in 22 patients (55%), edema in 15 (37.5%), a right 
fourth heart sound in 32 (80%), a loud pulmonary component 
of the second heart sound in 32 (80%), wide splitting of the 
second sound in 21 (52.5%), a systolic pulmonary murmur in 
28 (70%) and a diastolic pulmonary murmur in 18 (46%). 
ECG. Sinus rhythm was present in all patients, right-axis 
deviation in 29 (70%), right atrial hypertrophy in 24 (60%), 
right ventricular hypertrophy in 29 (72.5%), right ventricular 
strain in 37 (92.5%) and right bundle branch block in 5 
(12.5%). Hypertrophy and strain patterns were statistically 
correlated with pulmonary pressure (p < 0.01). 
Chest X-ray study. Cardiomegaly (cardiothoracic ratio 
>0.5) was present in 22 patients (55%), a prominent main 
pulmonary artery in 30 (75%), a right inferior lobe artery 
> 16 mm in diameter in 28 (87.5%) and pleural effusion in 6 
(15%). All these radiologic findings except pleural effusion 
correlated with pulmonary pressure (p < 0.05). 
Figure 1. Two-dimensional echocardiogram (transverse plane), 
showing an increase in right ventricular (RV) size with changes in 
ventricular septal motion. 
Pulmonary function tests. These data were obtained in 18 
patients. Mean vital capacity was 79.2 ± 28.8%, mean forced 
expiratory volume in 1 s/vital capacity 106.3 ± 9.6%; pul-
monary diffusion capacity for carbon monoxide 43.4 ± 
14.8%; partial pressure of oxygen (Po2) 74.4 ± 12.2; partial 
pressure of carbon dioxide (Pco2) 31.4 ± 9.2 and pH 7.4 ± 
0.1. None of these variables correlated with pulmonary 
artery pressure. 
Echocardiogram. All patients had various degrees of right 
chamber dilation and a characteristic pattern of pulmonary 
hypertension by Doppler echocardiography. These measure-
ments correlated with pulmonary pressure (p < 0.05; r = 0.80). 
Pericardia! effusion was present in 17 patients (42.5%) and 
abnormal ventricular septal motion in 13 (32.5%). A repre-
sentative echocardiogram is shown in Figure 1. 
Hemodynamic study (Table 1). As observed, the majority 
of patients had a pulmonary artery pressure at or near 
systemic level. All patients had a normal pulmonary capil-
lary wedge pressure, except Patient 37, who had mitral 
regurgitation secondary to a prolapsed mitral valve. Patient 
29 underwent cardiac catheterization in the coronary care 
unit while in severe cardiogenic shock and it was impossible 
to obtain the data that are missing in Table 1 because the 
patient died during the procedure. In all other patients, 
cardiac catheterization was uneventful. 
Causes of death (Table 2). Death was due to cardiogenic 
shock in 18 patients (54.5%) and respiratory failure, either 
muscular or parenchymal insufficiency, in 3 (9.1 %) and 4 
(10%) patients, respectively. Other causes of death are listed 
in Table 2. 
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Table 1. Hemodynamic Data From 24 of the 40 Victims of the Toxic Oil Syndrome 
SPAP DPAP MPAP PWP co SVR PVR 
PI No. (mm Hg) (mm Hg) (mm Hg) (mm Hg) (liters/min) (dynes·s·cm5) (dynes·s·cm5) 
2 75 45 55 15 3.5 1,250 1,940 
4 70 55 60 12 3.4 1,411 2,000 
5 60 35 44 4 4 880 1,700 
10 50 25 34 7 4.5 604 1,511 
14 82 23 50 3 3.8 1,616 1,520 
15 82 44 57 4 1,640 1,619 
17 75 52 60 5 2.4 2,000 2,833 
19 105 65 78 12 3.2 1,950 2,000 
20 130 55 85 10 2.3 2,956 2,956 
21 52 34 42 7 3.4 988 2,000 
23 80 40 55 8 1,442 2,229 
27 135 80 98 II 2.5 3,136 2,720 
29 185 82 116 
30 128 50 75 8 2.9 2,068 2,979 
31 125 60 80 2.8 2,222 2,500 
32 105 50 70 10 4 1,393 1,751 
33 70 38 47 6 4.7 795 1,420 
34 115 40 75 8 1.9 3,015 3,135 
35 76 45 56 10 3.2 1,378 2,166 
36 115 58 80 10 3.3 1,916 2,634 
37 75 40 54 26 2 2,097 3,495 
38 75 30 45 10 3.6 978 2,500 
39 62 34 46 10 3.4 1,066 2,461 
40 106 58 74 8 2.5 2,339 2,876 
Mean 93 47.4 64 9.2 3.25 2,305.1 I ,701.7 
± SD 32.3 15.2 19.5 4.8 0.7 583.3 714.3 
CO= cardiac output; DPAP =diastolic pulmonary artery pressure; MPAP = mean pulmonary artery pressure; 
Pt =patient; PVR =pulmonary vascular resistance; PWP =pulmonary wedge pressure; SPAP =systolic pulmonary 
artery pressure; SVR = systemic vascular resistance. 
Pathologic Studies 
Degree of pulmonary vascular damage according to the 
Heath and Edwards classification (Table 3). None of the 
patients presented with grade I or VI vascular damage. 
Grade III and IV involvement was observed in 53.5% and 
28.5% of patients, respectively; only 10.5% had grade II and 
7% grade V damage. Table 3 also lists the hemodynamic 
severity of pulmonary pressure in relation to the Heath and 
Edwards grading. Deaths occurring during 1981 to 1982 were 
associated with grade II lesions with less hemodynamic 
severity and were due chiefly to respiratory failure. In 
Table 2. Causes of Death in 33 Cases of Pulmonary Hypertension 
in Victims of the Toxic Oil Syndrome (1981 to 1988) 
Cardiogenic shock 
Acute respiratory insufficiency 
Respiratory muscle failure 
Sudden death 
Sepsis 


















contrast, during 1983 to 1986, grade III to V lesions appeared 
and the last death in 1987 was associated with grade V 
lesions. Patients with grade IV or V involvement died with 
low cardiac output and a higher pulmonary artery pressure 
(p < 0.05). Follow-up duration was statistically correlated 
with the degree of the vascular lesion (p < 0.01). Also, 
patients with syncope or edema, or both, had grade IV or V 
involvement (p < 0.001). 
Micromorphometric results (Table 4). All patients pre-
sented with medial hypertrophy >7% (mean 10.5 ± 5.2; 
range 8.3% to 19%). Medial layer thickness was increased in 
Table 3. Histologic Abnormalities in the Pulmonary Arteries 
Compared With Mean Pulmonary Artery Pressure in 28 Victims 
of the Toxic Oil Syndrome 
Mean Pulmonary 
Histologic Artery Pressure 
Degree No. of Cases (mmHg) 
I 0 (0%) 
II 3 (10.5%) 44 
Ill 15 (53.5%) 56 
IV 8 (28.5%) 89 
v 2 (7%) 77 
VI 0 (0%) 
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No. (%) Ecc Cone Plex Ven Thromb lnterst 
19 11.5* Yes Yes Yes Yes Yes Edema 
24 12.2* Yes No No Yes Yes Patchy fibrosis 
25 8.5* No Yes No Yes Yes Patchy fibrosis 
26 14.8* Yes Yes Yes Yes Yes Normal 
27 8.3* Yes Yes Yes Yes Yes Normal 
28 19* No Yes Yes Yes No Normal 
29 18.2* No Yes Yes Yes No Normal 
30 10.75* Yes Yes Yes Yes Yes Atelectasis 
31 14.3* Yes Yes Yes Yes Yes Patchy pneumonitis 
32 17.65* Yes Yes Yes Yes Yes Normal 
*Variation coefficient <0.33. Cone = concentric intimal fibrosis; Ecc = eccentric intimal fibrosis; lnterst = pulmonary interstitium; Plex = presence of 
plexiform lesion; Pt = patient; Thromb = presence of thrombus; Ven = venous affectation. 
relation to the years of illness. Intimal fibrosis (concentric or 
eccentric) was found in all patients, affecting both arteries 
and veins, with subsequent lumen obliteration. Seven of the 
10 patients had intraluminal thrombi in the pulmonary arter-
ies. The thrombi were in different stages of evolution. All 
except two patients had plexiform lesions. Finally, there was 
no diffuse parenchymal fibrosis in any patient. Patchy fi-
Figure 2. Spectrum of pulmonary vascular histopathologic features 
in the toxic oil syndrome. All magnifications are indicated with 
reference bars. A, Pulmonary artery with marked hypertrophy in 
medial layer between elastic layers (orcein). 8, Medium-sized vein 
showing intimal fibrosis (orcein). C, Arterial thrombi in recanaliza-
tion stage (hematoxylin and eosin). D, Plexiform lesion with extralu-
minal vascular channels (Masson trichrome). 
brosis secondary to previous respiratory infections were 
observed in three patients. Examples of the pathologic 
findings are presented in Figure 2. 
Tricuspid and pulmonary valves. Given the severity of 
pulmonary hypertension in most of these patients, major 
stress was placed on their tricuspid and pulmonary valves. 
Some of the pulmonary emboli observed in 70% of the 
patients studied morphometrically may have been related to 
vegetations, bland or septic, that formed as a consequence of 
valvular stress, as illustrated in one case (Fig. 3 and 4). In 
this 14-year old girl, bacterial endocarditis involved the 
tricuspid valve and numerous septic emboli and abundant 
nonseptic embolic debris were present throughout the pul-
monary vascular branches. 
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Figure 3. Small pulmonary arteries from a 14-year old girl 
with the toxic oil syndrome, pulmonary hypertension and 
tricuspid valve endocarditis. In A through C, there is an 
increasing amount of septic (bacterial) embolic debris 
associated with long-standing pulmonary artery narrow-
ing due primarily to intimal fibrosis with a mixture of 
fibroblasts, collagen and smooth muscle cells. Disruption 
of the vessel in C contains at least two large aggregates of 
bacteria (pentachrome). See also Figure 4. 
Discussion 
Pulmonary hypertension in the toxic oil syndrome. Epide-
miologic studies (7 ,8) have demonstrated that the toxic oil 
syndrome is related to the ingestion of denaturated rapeseed 
oil. Nevertheless, the specific toxic element or elements 
have not been identified, nor has the toxic oil syndrome been 
experimentally reproduced in all aspects. Although it is a 
multisystemic disease, one of its main features is pulmonary 
hypertension. In the first stage of this disease, pulmonary 
hypertension affected 20% of patients, occurring after the 
initial findings of acute pneumonitis and eosinophilia. This 
initial form of pulmonary hypertension usually regressed 
spontaneously in <2 years (9,10). The group of 40 patients in 
the present report correspond to a small subset whose 
pulmonary hypertension did not resolve. On the contrary, it 
became progressively more severe, leading to death in 33 
patients (82.5%) during a follow-up period of 6 years. This 
type of pulmonary hypertension found in the toxic oil 
syndrome is clinically and pathologically indistinguishable 
from primary pulmonary hypertension. Therefore, toxic oil 
syndrome may be added to the short list of diseases causing 
plexiform vascular lesions (11). 
Comparison with primary pulmonary hypertension. The 
clinical and hemodynamic data of the present study are 
similar to those of the National Prospective Study on Pri-
mary Pulmonary Hypertension with respect to the pulmo-
nary circulation. Nevertheless, there are important differ-
ences. l) The National Prospective Study (12) is a well 
designed prospective and multicenter study of 187 patients. 
The present study is retrospective from 1981 until 1983 
because at that time toxic oil syndrome was not well defined. 
Later, when it became evident that severe pulmonary hyper-
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tension was a major cause of death, the study became 
prospective. 2) The present study group corresponded to a 
previously normal population and the onset and evolution of 
the disease are precisely defined. This fact permits an 
analysis of clinical, hemodynamic and pathologic features 
and their mutual relation. In primary pulmonary hyperten-
sion, the clinical and pathologic features of the presymptom-
atic stage are unknown. 
Before the toxic oil syndrome epidemic occurred, 38 of 
the 40 patients had a normal heart. One patient (Case 37) 
had mitral valve prolapse and the other (Case 26) an old 
inferior myocardial infarction; both were asymptomatic. In 
all patients, new histologic lesions indicating an active 
pathologic process occurred as the physical signs, clinical 
symptoms and hemodynamic pulmonary hypertension pro-
gressed. 
The pulmonary vascular lesion in toxic oil syndrome. The 
vascular presentation of the pulmonary hypertension seen in 
the 1st 3 years of our study was primarily intimal prolifera-
tion and medial hypertrophy. Later, plexiform lesions ap-
peared, coinciding with marked clinical deterioration and 
intractable low cardiac output. Thrombi were more unpre-
dictable. In lung specimens obtained during the first stage of 
Figure 4. Same patient as in Figure 3. These two photo-
micrographs illustrate a shower of septic (bacterial) emboli 
visible as rounded dark masses obstructing the arterial 
lumens. There is extensive inflammation within and around 
the vessels. The area boxed in A is shown at higher 
magnification in B (Goldner trichrome). 
the disease (either from lung biopsy or autopsy material), 
pathologic findings showed primary endothelial injury, with 
cell proliferation and perivascular inflammatory infiltrates 
(13). This may be the initial substrate of further vascular 
lesions. 
With respect to the pathogenesis of pulmonary hyperten-
sion and vascular lesions, the initial endothelial injury 
produced by the toxic oil may be the triggering mechanism. 
The injured endothelium became thrombogenic, initiating 
myointimal cell migration and later creating medial hyper-
trophy and lumen obliteration. The link between the initial 
vascular lesion and the plexiform arteriopathy has not been 
demonstrated in the present study. Some authors (14) sug-
gested a previous vasculitis mechanism to create plexiform 
lesions, but fibrinoid necrosis was absent in previous stages 
of the disease in our pathologic material. Others (15) found 
an increase in the number of bronchiolar endocrine cells that 
were immunoreactive to bombesin and calcitonin. 
The preceding discussion does not explain why the initial 
pulmonary hypertension in the toxic oil syndrome (20% 
incidence) so often resolved spontaneously. A possible 
explanation for the preponderance of normalizing regression 
could be a decrease in the pulmonary inflammatory compo-
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nent, with subsequent altered vascular permeability. How-
ever, after this initial insult to the pulmonary vessels, healing 
is not complete morphologically because many vessels ex-
hibited different degrees of intimal proliferation. In fact, 
intimal fibrosis as the only abnormality has been shown in 
necropsy studies of patients without pulmonary hyperten-
sion who died in later stages. 
Patients with regression of pulmonary hypertension. The 
group of patients who initially developed pulmonary hyper-
tension in the acute phase of the disease, with subsequent 
regression (20% of the patients), was followed up for 5 years 
in our pulmonary hypertension clinic. Almost two-thirds of 
these patients presented with an abnormal pulmonary diffu-
sion capacity and variable degrees of effort dyspnea although 
they had no clinical features of pulmonary hypertension. In 
our attempt to explain these findings, 11 such patients 
underwent exercise during cardiac catheterization and their 
pulmonary artery pressure became significantly elevated 
during exercise (16). According to those data and our find-
ings in the present study, abnormal pulmonary diffusion 
capacity does not correlate with pulmonary artery pressure 
but can be considered a marker of the presence of pulmonary 
vascular lesions. 
Incidence of severe pulmonary hypertension. Because the 
incidence of severe pulmonary hypertension in the toxic oil 
syndrome (1.6 per 1 ,000) is similar to that of primary 
pulmonary hypertension in the general population (1. 7 to 2.3 
per 1 ,000) (17, 18), it is possible that there is an interaction 
between the toxic oil and specific individual susceptibility in 
the pathogenesis of pulmonary hypertension. This fact could 
explain why only a minority of toxic oil victims developed 
severe pulmonary hypertension. 
Conclusions. In the toxic oil syndrome, there are three 
types of pulmonary hypertension: 1) initial pulmonary hy-
pertension that accompanied the acute respiratory distress 
phase affected 20% of patients and then evolved spontane-
ously to normalization; 2) severe and often lethal pulmonary 
hypertension indistinguishable from the primary form of 
pulmonary hypertension affected 1.6 per 1,000; and 3) dy-
namic pulmonary hypertension was found in patients with 
effort dyspnea and abnormal pulmonary diffusion capacity. 
The eventual incidence of this latter form and its ultimate 
evolution are as yet unknown. 
References 
I. Toxic Epidemic Syndrome Study Group. Toxic epidemic syndrome, 
Spain 1981. Lancet 1982;2:697-702. 
2. Martin Escribano P, Fernandez Sanchez Alarcos JM, Dominguez-Lozano 
MJ, et al. Exploration fonctionnelle pulmonaire aux differents stades du 
syndrome du a l'huile toxique. Bull Eur Physiopathol Respir 1984;20:307-
12. 
3. Gomez-Sanchez MA, Mestre de Juan MJ, Gomez-Pajuelo C, Lopez JI, 
Diaz de Atauri MJ, Martinez-Tello FJ. Pulmonary hypertension due to 
toxic oil syndrome: a clinicopathologic study. Chest 1989;95:325-31. 
4. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascu-
lar disease: description of six grades of structural changes in the pulmo-
nary arteries with special reference to congenital cardiac septal defects. 
Circulation 1958;18:533-47. 
5. Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung 
biopsy in congenital heart disease: a morphometric approach to pulmo-
nary vascular disease. Circulation 1978;58:1107-22. 
6. Katzenstein AL, Askin FB. Surgical pathology of non-neoplastic lung 
disease. In: Bennington JL, ed. Major Problems in Pathology, vol 12. 
Philadelphia: WB Saunders, 1982:281-313. 
7. Tabuenca JM. Toxic-allergic syndrome caused by ingestion of rapeseed 
oil denatured with aniline. Lancet 1981 ;2:567-8. 
8. Kilbourne EM, Berner! JT Jr., Posada de Ia Paz M, et al., and The 
Toxico-Epidemiologic Study Group. Chemical correlates of pathogenicity 
of oils related to the toxic oil syndrome epidemic in Spain. Am J 
Epidemiol1988;127:1210-27. 
9. Gomez Recio M, Martinez Elbal L, Rodrigo Lopez SL, Salva Aliem J, 
Alcazar Abajar J, Zarco Gutierrez P. Hipertension pulmonar en el 
sindrome toxico. N Arch Fac Med 1983;41:237-44. 
10. Garcia-Dorado D, Douglas Miller D, Garcia EJ, Delcan J-L, Maroto E, 
Chaitman BR. An epidemic of pulmonary hypertension after toxic rape-
seed oil ingestion in Spain. JAm Coli Cardiol1983;1:1216-22. 
II. Mestre de Juan MJ, Martinez Tello FJ, Gomez-Pajuelo C, et al. Severe 
pulmonary hypertension due to toxic oil syndrome: a new cause of 
plexogenic arteriopathy. Cor Vasa 1990;32:218-24. 
12. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: 
a national prospective study. Ann Intern Med 1987;107:216-23. 
13. Martinez Tello FJ, Navas Palacios JJ, Ricoy JR, et al. Pathology of a new 
toxic syndrome caused by ingestion of adulterated oil in Spain. Virchows 
Arch (A) 1982;397:261-85. 
14. Fishman AP. Plexiform lesions. Pathol Microbiol Basel 1975;43:242-5. 
15. Heath D, Smith P, Gosney J, et al. The pathology of the early and late 
stages of primary pulmonary hypertension. Br Heart J 1987;58:204-13. 
16. Gomez-Sanchez MA, Diaz de Atauri F, Alonso Gutierrez A, et al. 
Dynamic pulmonary arterial hypertension in patients with impaired 
pulmonary diffusing capacity due to toxic oil syndrome. Cor Vasa 
1990;32:211-7. 
17. Wood P. Pulmonary hypertension. In: Wood P, ed. Diseases of the Heart 
and Circulation, 3rd ed. London: Eyre and Spottiswoode, 1968:796-810. 
18. Nielsen NC, Fabricius J. Primary pulmonary hypertension, with special 
reference to prognosis. Acta Med Scand 1961;170:731-41. 
